Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2020 Mar 1;77(3):300-308.
doi: 10.1001/jamaneurol.2019.4113.

Fenfluramine for Treatment-Resistant Seizures in Patients With Dravet Syndrome Receiving Stiripentol-Inclusive Regimens: A Randomized Clinical Trial

Rima Nabbout  1 , Arun Mistry  2 , Sameer Zuberi  3 , Nathalie Villeneuve  4 , Antonio Gil-Nagel  5 , Rocio Sanchez-Carpintero  6 , Ulrich Stephani  7 , Linda Laux  8 , Elaine Wirrell  9 , Kelly Knupp  10 , Catherine Chiron  11 , Gail Farfel  2 , Bradley S Galer  2 , Glenn Morrison  2 , Michael Lock  2 , Anupam Agarwal  2 , Stéphane Auvin  12 ; FAiRE, DS Study Group
Affiliations
Randomized Controlled Trial

Fenfluramine for Treatment-Resistant Seizures in Patients With Dravet Syndrome Receiving Stiripentol-Inclusive Regimens: A Randomized Clinical Trial

Rima Nabbout et al. JAMA Neurol. .

Abstract

Importance: Fenfluramine treatment may reduce monthly convulsive seizure frequency in patients with Dravet syndrome who have poor seizure control with their current stiripentol-containing antiepileptic drug regimens.

Objective: To determine whether fenfluramine reduced monthly convulsive seizure frequency relative to placebo in patients with Dravet syndrome who were taking stiripentol-inclusive regimens.

Design, setting, and participants: This double-blind, placebo-controlled, parallel-group randomized clinical trial was conducted in multiple centers. Eligible patients were children aged 2 to 18 years with a confirmed clinical diagnosis of Dravet syndrome who were receiving stable, stiripentol-inclusive antiepileptic drug regimens.

Interventions: Patients with 6 or more convulsive seizures during the 6-week baseline period were randomly assigned to receive fenfluramine, 0.4 mg/kg/d (maximum, 17 mg/d), or a placebo. After titration (3 weeks), patients' assigned dosages were maintained for 12 additional weeks. Caregivers recorded seizures via a daily electronic diary.

Main outcomes and measures: The primary efficacy end point was the change in mean monthly convulsive seizure frequency between fenfluramine and placebo during the combined titration and maintenance periods relative to baseline.

Results: A total of 115 eligible patients were identified; of these, 87 patients (mean [SD], age 9.1 [4.8] years; 50 male patients [57%]; mean baseline frequency of seizures, approximately 25 convulsive seizures per month) were enrolled and randomized to fenfluramine, 0.4 mg/kg/d (n = 43) or placebo (n = 44). Patients treated with fenfluramine achieved a 54.0% (95% CI, 35.6%-67.2%; P < .001) greater reduction in mean monthly convulsive seizure frequency than those receiving the placebo. With fenfluramine, 54% of patients demonstrated a clinically meaningful (≥50%) reduction in monthly convulsive seizure frequency vs 5% with placebo (P < .001). The median (range) longest seizure-free interval was 22 (3.0-105.0) days with fenfluramine and 13 (1.0-40.0) days with placebo (P = .004). The most common adverse events were decreased appetite (19 patients taking fenfluramine [44%] vs 5 taking placebo [11%]), fatigue (11 [26%] vs 2 [5%]), diarrhea (10 [23%] vs 3 [7%]), and pyrexia (11 [26%] vs 4 [9%]). Cardiac monitoring demonstrated no clinical or echocardiographic evidence of valvular heart disease or pulmonary arterial hypertension.

Conclusions and relevance: Fenfluramine demonstrated significant improvements in monthly convulsive seizure frequency in patients with Dravet syndrome whose conditions were insufficiently controlled with stiripentol-inclusive antiepileptic drug regimens. Fenfluramine was generally well tolerated. Fenfluramine may represent a new treatment option for Dravet syndrome.

Trial registration: ClinicalTrials.gov identifier: NCT02926898.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest Disclosures: Drs Nabbout, Auvin, Zuberi, Villeneuve, Gil-Nagel, Sanchez-Carpintero, Stephani, Laux, Wirrell, Knupp, and Chiron report research support from Zogenix outside the submitted work. Drs Farfel, Galer, Morrison, Mistry, and Agarwal are employees of and owners of stock from Zogenix. Dr Lock reported receiving personal fees as a consultant to Zogenix both during the conduct of this study and outside of the submitted work. Dr Sanchez-Carpintero also reported personal fees and other support from GWPharma outside the submitted work and unremunerated membership in the Scientific committee for Fundación Síndrome de Dravet. Dr Stephani also reported being part of the advisory board of Zogenix and a speaker at a Zogenix industrial symposium during an international congress. Dr Knupp also reported personal fees from GWPharma, Stoke Therapeutics, and Biomarin and grants from West Therapeutics outside the submitted work. Dr Chiron also reported personal fees from Advicenne, Biocodex, Orphelia, UCB, and Zogenix outside the submitted work. Dr Farfel reported the following patents pending: US20180092864, US20190125697, US20190091173, US20190091174, and 2 additional unpublished patent applications. Dr Galer also reported support from Zogenix outside the submitted work and patent to Zogenix. Dr Morrison also reported personal fees from Zogenix outside the submitted work; in addition, Dr Morrison had the following patents pending: US20190091179, US20190091175, US20190091176, US20190091177 and another unpublished patent. Dr Auvin also reports personal fees from Arvelle and Biocodex; personal fees and nonfinancial support from Biomarin, GWPharma, and Nutricia; personal fees and grants from Eisai, UCB Pharma, and Advicenne Pharma for work as an investigator; and nonfinancial support from Vitaflo. Dr Gil-Nagel also reports personal fees from Bilal, GWPharma, Zogenix, Stoke Therapeutics, Eisai, and Esteve. No other disclosures were reported.

Figures

Figure 1.
Figure 1.. Patient Disposition
OLE indicates open-label extension.
Figure 2.
Figure 2.. Cumulative Response Curves for Percent Reduction in Monthly Convulsive Seizure Frequency From Baseline
Results are plotted for combined titration and maintenance periods. Vertical dashed lines represent 25%, 50%, and 75% reduction in monthly convulsive seizure frequencies; percentages correspond to the proportion of patients in the fenfluramine or placebo groups who met or exceeded each response level. Twelve of 44 patients (27%) in the placebo group and 30 of 43 (70%) in the fenfluramine group experienced 25% or greater reductions (P < .001); 2 of 44 patients (5%) in the placebo group and 23 of 43 (54%) in the fenfluramine group experienced 50% or greater reductions (P < .001); and 1 of 44 (2%) in the placebo group and 15 of 43 (35%) in the fenfluramine group experienced 75% reductions (P = .003). The P values are vs placebo and are estimated by logistic regression (as per Table 2).
See this image and copyright information in PMC

Comment in

  • You Can Teach an Old Drug New Tricks.
    Perry MS. Perry MS. Epilepsy Curr. 2020 May 12;20(4):193-195. doi: 10.1177/1535759720923035. eCollection 2020 Jul-Aug. Epilepsy Curr. 2020. PMID: 34025226 Free PMC article. No abstract available.

References

    1. Wirrell EC, Laux L, Donner E, et al. . Optimizing the diagnosis and management of Dravet syndrome: recommendations from a North American consensus panel. Pediatr Neurol. 2017;68:18-34.e3. doi:10.1016/j.pediatrneurol.2017.01.025 - DOI - PubMed
    1. Wu YW, Sullivan J, McDaniel SS, et al. . Incidence of Dravet syndrome in a US population. Pediatrics. 2015;136(5):e1310-e1315. doi:10.1542/peds.2015-1807 - DOI - PMC - PubMed
    1. Dravet C, Bureau M, Oguni H, Fukuyama Y, Cokar O. Severe myoclonic epilepsy in infancy: Dravet syndrome. Adv Neurol. 2005;95:71-102. - PubMed
    1. Depienne C, Trouillard O, Saint-Martin C, et al. . Spectrum of SCN1A gene mutations associated with Dravet syndrome: analysis of 333 patients. J Med Genet. 2009;46(3):183-191. doi:10.1136/jmg.2008.062323 - DOI - PubMed
    1. Skluzacek JV, Watts KP, Parsy O, Wical B, Camfield P. Dravet syndrome and parent associations: the IDEA League experience with comorbid conditions, mortality, management, adaptation, and grief. Epilepsia. 2011;52(suppl 2):95-101. doi:10.1111/j.1528-1167.2011.03012.x - DOI - PubMed

Publication types

Associated data